CVRx Inc. launches a European registry to track treatment with its Barostim neo heart implant for patients with drug-resistant hypertension.
MASSDEVICE ON CALL — Minneapolis-based CVRx Inc. launched a European registry to track treatment with its Barostim neo device, a heart implant for treatment of drug-resistant hypertension.
The Barostim neo device is designed to trigger the body's natural blood flow regulation system by activating the baroreceptors, located in the carotid artery, which regulate cardiovascular function.
The stimulation effectively tells the arteries to relax, the heart to slow down and the kidneys to reduce fluid in the body, resulting in reduced cardiac exertion, reducing the workload on the heart, according to a press release.
The new registry is expected to enroll up to 500 patients and track performance outcomes and physician experience.
MicroVention launches study of coiling technologies for brain aneurysms
Tustin, Calif.-based MicroVention began enrollment in a clinical trial comparing coiling technologies used to treat intracranial aneurysms.
The prospective, randomized, international multicenter trial will enroll up to 600 subjects in a study pitting new generation MicroVention hydrogen coils against bare platinum coils.
Hospitals are using Google's reality-augmenting Glass technology to help sick kids and better treat...
Former Stryker executive Mark Foldy, who pleaded guilty last year for his part in an insider trading...
Sales and profits were down during the 1st quarter for GE Healthcare, which cited "market volatility...
Vital Therapies once again lowers the bar on its initial public offering, pricing the flotation at $...
Here's a look at some of the top Wall Street stories for medical device companies this week.